331 related articles for article (PubMed ID: 36776828)
1. JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an
Frede N; Lorenzetti R; Hüppe JM; Janowska I; Troilo A; Schleyer MT; Venhoff AC; Voll RE; Thiel J; Venhoff N; Rizzi M
Front Immunol; 2023; 14():1087986. PubMed ID: 36776828
[TBL] [Abstract][Full Text] [Related]
2. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
3. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
[TBL] [Abstract][Full Text] [Related]
4. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R
Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
7. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H
Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336
[TBL] [Abstract][Full Text] [Related]
8. JAK inhibitors for rheumatoid arthritis.
Kubo S; Nakayamada S; Tanaka Y
Expert Opin Investig Drugs; 2023 Apr; 32(4):333-344. PubMed ID: 37014106
[TBL] [Abstract][Full Text] [Related]
9. Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis.
Garufi C; Maclean M; Gadina M; Spinelli FR
Expert Rev Clin Immunol; 2022 Mar; 18(3):309-319. PubMed ID: 35168456
[TBL] [Abstract][Full Text] [Related]
10. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Keeling S; Maksymowych WP
Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
[TBL] [Abstract][Full Text] [Related]
11. Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors.
Hu L; Liu R; Zhang L
Int Immunopharmacol; 2022 Oct; 111():109095. PubMed ID: 35926270
[TBL] [Abstract][Full Text] [Related]
12. JAK inhibition in the treatment of inflammatory rheumatic diseases.
Šenolt L
Vnitr Lek; 2023; 69(3):181-188. PubMed ID: 37468313
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).
Parmentier JM; Voss J; Graff C; Schwartz A; Argiriadi M; Friedman M; Camp HS; Padley RJ; George JS; Hyland D; Rosebraugh M; Wishart N; Olson L; Long AJ
BMC Rheumatol; 2018; 2():23. PubMed ID: 30886973
[TBL] [Abstract][Full Text] [Related]
16. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis.
Biggioggero M; Becciolini A; Crotti C; Agape E; Favalli EG
Drugs Context; 2019; 8():212595. PubMed ID: 31692920
[TBL] [Abstract][Full Text] [Related]
17. Treatment of rheumatoid arthritis with baricitinib or upadacitinib is associated with reduced scaffold protein NEDD9 levels in CD4+ T cells.
Golumba-Nagy V; Yan S; Steinbach-Knödgen E; Thiele J; Esser RL; Haak TH; Nikiforov A; Meyer A; Seeger-Nukpezah T; Kofler DM
Physiol Rep; 2023 Oct; 11(19):e15829. PubMed ID: 37771106
[TBL] [Abstract][Full Text] [Related]
18. Selective JAK inhibitors in development for rheumatoid arthritis.
Norman P
Expert Opin Investig Drugs; 2014 Aug; 23(8):1067-77. PubMed ID: 24818516
[TBL] [Abstract][Full Text] [Related]
19. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
20. Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
Emori T; Kasahara M; Sugahara S; Hashimoto M; Ito H; Narumiya S; Higashi Y; Fujii Y
Eur J Pharmacol; 2020 Sep; 882():173238. PubMed ID: 32561292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
